Connect your AI

Aurinia Pharmaceuticals AUPH Net debt

Discontinued — last reported Q1 '26

Net debt at other companies

Sonos, Inc.SONO

-0.4×—

ANI PharmaceuticalsANIP

-0×-2.5×

Global Net LeaseGNL

-0.2×-0.1×

Healthcare Services GroupHCSG

-1.3×-22.6×

Global PartnersGLP

1.7×+0.2×

Ivanhoe ElectricIE

-19.6×—

Other financials

Income statement

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

Operating cash flow$32.6M+2,405%

Valuation

Market cap$2.39B+78.5%

Profitability

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Calculated from Aurinia Pharmaceuticals’s reported figures.

$85.2Mtotal debt−$41.0Mcash and equivalents=$44.15M

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's net debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Aurinia Pharmaceuticals's net debt?: Aurinia Pharmaceuticals (AUPH) reported net debt of $44.15M in Q1 2026.
How has Aurinia Pharmaceuticals's net debt changed year-over-year?: Aurinia Pharmaceuticals's net debt increased by 69.9% year-over-year, from $25.99M to $44.15M.
What is the long-term trend for Aurinia Pharmaceuticals's net debt?: Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's net debt has grown at a -46.9% compound annual growth rate (CAGR), from -$263.94M to $11.12M.
What does net debt mean?: Total debt minus cash and equivalents at the quarter end. The debt that would remain if the company used all its cash to pay down borrowings.